Parkinson Disease - Market Insights, Epidemiology and Market Forecast – 2023 - EU5

  • ID: 4052916
  • Drug Pipelines
  • 88 pages
  • DelveInsight
1 of 3
“Parkinson Disease - Market Insights, Epidemiology and Market Forecast – 2023 - EU5” Reports provides an overview of the disease and global market size of the Parkinson Disease for the EU5. It also includes global historical and forecasted epidemiological data for the diagnosed prevalent cases of Parkinson Disease from 2010-2023. According to Publisher, the forecasted patient population of Parkinson Disease will increase at a CAGR of XX% from 2010 to 2023 and the worldwide Parkinson Disease market is estimated to be USD XX Million by 2023.

Parkinson's disease (PD) is a disorder caused by the malfunction and death of neurons. It is a chronic and progressive movement disorder which primarily affects neurons in substantia nigra area of the brain. Dopamine is usually responsible for the control and coordination process which is affected when the neuron malfunction and death occurs. As the disease progresses, the amount of dopamine produced in the brain decreases as a result the person is unable to control movement normally. This degenerative disorder affects the central nervous system.

Scope:
- Report covers the disease overview including pathophysiology, symptoms, diagnosis, disease management, and current treatment options.
- Marketed information including available prescription drugs, its patent and exclusivity details.
- The Report also covers the detailed global historical and forecasted epidemiological data covering EU5 from 2010-2023.
- It also provides Market size of Parkinson disease for EU5 from 2010 and forecasted Market size to 2023.

Note: This report will be delivered within 24 hours of purchase.
Note: Product cover images may vary from those shown
2 of 3
Report Introduction
Parkinson Disease Market Overview at a Glance
Total Market Size of Parkinson Disease for 7 MM in 2013-2023
Total Market Share Distribution of Parkinson Disease for 7 MM in 2015
Total Market Share Distribution of Parkinson Disease for 7 MM in 2023
Parkinson Disease
Overview
Symptoms
Pathophysiology
Staging
Diagnosis
Treatment
Epidemiology and Patient Population
Germany
Diagnosed Cases of Parkinson Disease in Germany
France
Diagnosed Cases of Parkinson Disease in France
United Kingdom
Diagnosed Cases of Parkinson Disease in United Kingdom
Spain
Diagnosed Cases of Parkinson Disease in Spain
Italy
Diagnosed Cases of Parkinson Disease in Italy
Marketed Drugs
Top Marketed Drugs for Parkinson disease
Azilect: Teva Pharmaceutical Industries
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Azilect
Product Profile
Exelon/Exelon Patch: Novartis
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Exelon
Product Profile
Stalevo: Orion Corporation
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Stalevo
Product Profile
Comtan/Comtess: Orion Corporation
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Comtan/Comtess
Product Profile
Emerging Therapies
Major Pipeline drugs
Istradefylline
Regulatory Milestones
Advantages & Disadvantages
Product Profile
Clinical Development
Clinical Pipeline Activity
Ongoing Trials Information
Clinical Trial by Phase
Tozadenant
Advantages & Disadvantages
Product Profile
Clinical Development
Clinical Pipeline Activity
Ongoing Trials Information
Clinical Trial by Phase
CVT-301
Product Profile
Clinical Development
Clinical Pipeline Activity
Ongoing Trials Information
Clinical Trial by Phase
Global Parkinson Disease: Country-Wise Market Analysis
Overview on Total Parkinson Disease Market (2015 & 2023)
Europe Market Size
Germany Market Size
France Market Size
United Kingdom Market Size
Spain Market Size
Italy Market Size
Market Drivers
Market Restraints
Appendix
Report Methodology
Consulting Services
Disclaimer
About Us

List of Tables
Table 1: Diagnosed Cases Parkinson Disease in Germany (2010-2023)
Table 2: Diagnosed Cases Parkinson Disease in France (2010-2023)
Table 3: Diagnosed Cases Parkinson Disease in United Kingdom (2010-2023)
Table 4: Diagnosed Cases Parkinson Disease in Spain (2010-2023)
Table 5: Diagnosed Cases Parkinson Disease in Italy (2010-2023)
Table 6: List of Marketed Drugs for Parkinson Disease
Table 7: List of Pipeline Phase III Drugs for Parkinson Disease
Table 8: Istradefylline, Clinical Trials by Zone, 2016
Table 9: Clinical Trials by Trial status, 2016
Table 10: Tozadenant, Clinical Trials by Zone, 2016
Table 11: Clinical Trials by Trial status, 2016
Table 12: CVT-301, Clinical Trials by Zone, 2016
Table 13: Clinical Trials by Trial status, 2016
Table 14: United States Market Size of Parkinson Disease in USD, Million (2010-2023)
Table 15: Germany Market Size of Parkinson Disease in USD, Million (2010-2023)
Table 16: France Market Size of Parkinson Disease in USD, Million (2010-2023)
Table 17: United Kingdom Market Size of Parkinson Disease in USD, Million (2010-2023)
Table 18: Spain Market Size of Parkinson Disease in USD, Million (2010-2023)
Table 19: Italy Market Size of Parkinson Disease in USD, Million (2010-2023)
Table 20: Japan Market Size of Parkinson Disease in USD, Million (2010-2023)

List of Figures
Figure 1: Types of Parkinson Disease
Figure 2: Types of Parkinson Disease
Figure 3: Diagnosed Cases of Parkinson Disease in Germany (2010-2023)
Figure 4: Diagnosed Cases of Parkinson Disease in France (2010-2023)
Figure 5: Diagnosed Cases of Parkinson Disease in United Kingdom (2010-2023)
Figure 6: Diagnosed Cases of Parkinson Disease in Spain (2010-2023)
Figure 7: Diagnosed Cases of Parkinson Disease in Italy (2010-2023)
Figure 8: Istradefylline, Clinical Trials by Zone (%), 2016
Figure 9: Istradefylline, Clinical Trials by Trial status (%), 2016
Figure 10: Tozadenant, Clinical Trials by Zone (%), 2016
Figure 11: Istradefylline, Clinical Trials by Trial status (%), 2016
Figure 12: CVT-301, Clinical Trials by Zone (%), 2016
Figure 13: CVT-301, Clinical Trials by Trial status (%), 2016
Figure 14: Total Market Size of Parkinson Disease in USD, Million (2015)
Figure 15: Total Market Size of Parkinson Disease in USD, Million (2023)
Figure 16: Germany Market Size of Parkinson Disease in USD, Million (2010-2023)
Figure 17: France Market Size of Parkinson Disease in USD, Million (2010-2023)
Figure 18: United Kingdom Market Size of Parkinson Disease in USD, Million (2010-2023)
Figure 19: Spain Market Size of Parkinson Disease in USD, Million (2010-2023)
Figure 20: Italy Market Size of Parkinson Disease in USD, Million (2010-2023)
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll